|FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $398.1M|
The Series A financing was led by Advent International and included investments from Index Ventures, Alta Partners and MVM Life Science Partners
The Series B financing was led by Venrock Associates and included founding investors Atlas Venture, Flagship Ventures and Polaris Venture Partners; Adnexus formerly was named Compound Therapeutics Inc.
Amsterdam, the Netherlands
Investors in the third-round financing were the Van Herk Group and Gilde Healthcare
Colt Ventures LLC was lead investor in the Series A financing round
Telegraph Hill Partners led the Series A financing of Asuragen, an Ambion Inc. spin-off; Growth Capital Partners and other Ambion investors also participated
The financing was provided by the German MIG funds
The company secured a $5M venture debt commitment from Lighthouse Capital Partners
The Series B financing included Series A investors along with new venture and investment banking investors
CoGenesys was spun out of Human Genome Sciences Inc.; the Series A financing was led by New Enterprise Associates and included investments by OrbiMed Advisors, Red Abbey Venture Partners and Human Genome Sciences
The Series A stock was sold to institutional and other accredited investors; Riverbank Capital Securities Inc. was placement agent
Cedar Knolls, N.J.
The company completed its first institutional funding, which was led by NewSpring Capital and ESP Equity Partners
The Series B round was led by New Enterprise Associates and included existing investors Alliance Technology Ventures, Anthem Capital Management, The Novartis Venture Fund, PTV Sciences LP and The Maryland Department of Business and Economic Development
The Series A financing was made by institutional investors; Paramount BioCapital Inc. was lead placement agent; Punk, Ziegel & Co. was co-agent
Lifeblood completed a $2.2M Series B financing, following the $1M Series A round completed in March
Investors in the Series D round included Konishi Hiroshi, Kenso Kogyo Co. Ltd., Kyokuto Securities Co. Ltd., Medikit Co. Ltd., Mizuho Capital Co. Ltd., Nomura Research & Advisory Co. Ltd., Shin Nihon Jitsugyo Co. Ltd. and Softbank Investment Corp.
The Series C financing was led by Warburg Pincus and included other existing investors ABS Ventures, Axiom Venture Partners, Cardinal Partners, EuclidSR Partners, Oxford Bioscience, Partners and S.R. One Ltd., along with new investors MedImmune Ventures Inc. and Radius Ventures
King of Prussia, Pa.
The Series B financing was led by Bain Capital LLC and Quaker BioVentures and included previous investors Oak Investment Partners, Johnson and Johnson Development Corp., HealthCap and L Capital Partners
The Series B financing was led by Latterell Venture Partners and included new investors Quaker BioVentures, the Vertical Group and Amgen Ventures and existing investors HealthCare Ventures, PA Early Stage Partners and Kammerer Associates
The first $20M tranche in a potential $55M Series B financing was led by Texas Pacific Group Ventures and included existing investors MPM Capital, ARCH Venture Partners, OVP Venture Partners and Amgen Ventures, and new investors MedImmune Ventures Inc. and WRF Capital
|Currency conversions are based on exchange rates at the time of the deal.|
|ND = Not disclosed.|